Reasons Behind the Decline of BioNano Genomics (BNGO) Stock on Tuesday
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 16 2025
0mins
Should l Buy BNGO?
Source: Benzinga
Public Offering Announcement: BioNano Genomics Inc. is offering 5 million shares of common stock at $2.00 per share, aiming to raise approximately $10 million for working capital and corporate purposes.
Stock Price Reaction: Following the announcement, BNGO shares fell by 38.45% to $1.705, reflecting concerns over potential share dilution and a low growth score of 16.40.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BNGO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BNGO
Wall Street analysts forecast BNGO stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.090
Low
7.00
Averages
7.50
High
8.00
Current: 1.090
Low
7.00
Averages
7.50
High
8.00
About BNGO
Bionano Genomics, Inc. is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bionano Genomics Announces 2026 Symposium for Optical Genome Mapping Community
- Global Event: Bionano Genomics has announced the Bionano Symposium 2026, scheduled for February 23-26, 2026, which will gather over 30 researchers from North America, Europe, and Asia to showcase cutting-edge applications of optical genome mapping (OGM), potentially advancing research in this field.
- Diverse Applications: The symposium will cover multiple research areas including hematologic malignancies, solid tumors, bioprocessing, genetic disorders, and gene and cell therapy, highlighting OGM's advantages in identifying pathogenic structural variants and streamlining laboratory workflows, thereby enhancing research efficiency.
- Showcasing Technological Innovations: The event will feature scientific presentations, interactive discussions, and a virtual poster hall, providing participants with insights into how OGM serves as a cornerstone tool in modern cytogenetics and genome analysis, thereby deepening the scientific community's understanding of genomic complexity.
- Free Registration Opportunity: Registration for the event is free, and Bionano encourages researchers from the global OGM community to submit posters to showcase their work, further promoting scientific exchange and collaboration.
See More
Bionano Genomics Showcases OGM Technology Enhancing Detection Capabilities
- Technology Showcase: Bionano Genomics presented its Optical Genome Mapping (OGM) technology at the 2025 AMP Annual Meeting, highlighting its superior clarity and sensitivity in detecting structural variants compared to traditional methods, which may drive broader clinical adoption.
- Research Findings: A total of thirteen studies were presented, indicating the increasing application of OGM in areas such as inherited diseases and tumors, showcasing its potential as a high-resolution genomic technique that could transform the study of complex diseases.
- Workflow Optimization: Researchers demonstrated the successful integration of OGM into existing cytogenetics and next-generation sequencing (NGS) pipelines, streamlining laboratory workflows and enhancing efficiency in both clinical and translational research settings.
- Future Outlook: Bionano CEO Erik Holmlin stated that the advancement of OGM will enable comprehensive structural variant analysis to become routine, efficient, and accessible in laboratories, signaling a strategic shift for the company in the genomics field.
See More
Bionano Genomics Showcases OGM Technology for Enhanced Structural Variant Detection
- Technology Application Showcase: Bionano Genomics presented its optical genome mapping (OGM) technology at the 2025 AMP Annual Meeting, highlighting its superior clarity and sensitivity in detecting structural variants compared to traditional techniques, which is expected to drive broader applications in clinical and translational research.
- Research Findings Summary: A total of thirteen studies presented at the conference demonstrated OGM's potential in areas such as inherited diseases and tumors, indicating its capability as a high-resolution genomic technique that could transform the understanding of genetic mechanisms driving complex diseases.
- Laboratory Workflow Optimization: Researchers showcased how OGM can be successfully integrated into existing cytogenetics and next-generation sequencing workflows, streamlining laboratory processes and enhancing detection efficiency, which may improve operational effectiveness in labs.
- Future Development Commitment: Bionano CEO Erik Holmlin stated the company's commitment to innovating and expanding OGM technology, aiming to make comprehensive structural variant analysis routine, efficient, and accessible in laboratories, signaling a promising future market outlook.
See More
Bionano Laboratories Sees 47% Increase in 2026 CLFS for OGM Testing
- Fee Increase: Bionano Laboratories' CPT code 81195 sees a 47% increase in the 2026 Clinical Laboratory Fee Schedule, rising from $1,263.53 to $1,853.22, which will significantly enhance reimbursement for OGM testing related to blood cancers, thereby strengthening market competitiveness.
- Committee Support: The Clinical Diagnostic Laboratory Test Committee unanimously voted 10-0 in favor of reconsidering the payment standard for CPT code 81195, indicating strong industry recognition and confidence in OGM technology.
- Market Impact: The new pricing is expected to make Bionano's OGM-Dx™ product line more attractive, likely driving market share growth in hematologic malignancy testing and further solidifying its leadership position in genome analysis.
- Global Recognition: Bionano's Chief Medical Officer stated that the new payment level will not only facilitate the promotion of OGM testing in the U.S. market but also enhance global awareness of OGM applications in oncology and clinical genetic testing.
See More
Baidu Expected to Surge Over 69%: 10 Leading Analyst Predictions for Monday
Analyst Upgrades and Price Target Increases: JP Morgan upgraded Cipher Mining Inc and Baidu Inc, raising their price targets significantly, while B of A Securities upgraded Barrick Mining Corp's rating and price target as well.
Analyst Downgrades and Price Target Reductions: HC Wainwright & Co. downgraded BioNano Genomics Inc, and Jefferies downgraded Exact Sciences Corp despite increasing their price targets.
Mixed Analyst Ratings: Various analysts maintained or adjusted ratings for companies like Mp Materials Corp and Flutter Entertainment PLC, with some upgrades and downgrades occurring simultaneously.
Current Stock Prices: The article provides the latest closing prices for the mentioned stocks, indicating market performance and analyst sentiment.
See More
Bionano Genomics Initiates $10 Million Public Offering
Public Offering Announcement: Bionano Genomics, Inc. has launched a public offering of 5 million shares at $2.00 each, aiming to raise $10 million, with potential additional funds of $20 million if warrants are fully exercised.
Strategic Focus and Growth Plans: The company is enhancing utilization of its optical genome mapping and VIA software, aiming to expand into clinical and anatomic pathology while developing reimbursement support to increase profits and reduce costs.
See More
Bionano Genomics Announces 2026 Symposium for Optical Genome Mapping Community
- Global Event: Bionano Genomics has announced the Bionano Symposium 2026, scheduled for February 23-26, 2026, which will gather over 30 researchers from North America, Europe, and Asia to showcase cutting-edge applications of optical genome mapping (OGM), potentially advancing research in this field.
- Diverse Applications: The symposium will cover multiple research areas including hematologic malignancies, solid tumors, bioprocessing, genetic disorders, and gene and cell therapy, highlighting OGM's advantages in identifying pathogenic structural variants and streamlining laboratory workflows, thereby enhancing research efficiency.
- Showcasing Technological Innovations: The event will feature scientific presentations, interactive discussions, and a virtual poster hall, providing participants with insights into how OGM serves as a cornerstone tool in modern cytogenetics and genome analysis, thereby deepening the scientific community's understanding of genomic complexity.
- Free Registration Opportunity: Registration for the event is free, and Bionano encourages researchers from the global OGM community to submit posters to showcase their work, further promoting scientific exchange and collaboration.
See More
Bionano Genomics Showcases OGM Technology Enhancing Detection Capabilities
- Technology Showcase: Bionano Genomics presented its Optical Genome Mapping (OGM) technology at the 2025 AMP Annual Meeting, highlighting its superior clarity and sensitivity in detecting structural variants compared to traditional methods, which may drive broader clinical adoption.
- Research Findings: A total of thirteen studies were presented, indicating the increasing application of OGM in areas such as inherited diseases and tumors, showcasing its potential as a high-resolution genomic technique that could transform the study of complex diseases.
- Workflow Optimization: Researchers demonstrated the successful integration of OGM into existing cytogenetics and next-generation sequencing (NGS) pipelines, streamlining laboratory workflows and enhancing efficiency in both clinical and translational research settings.
- Future Outlook: Bionano CEO Erik Holmlin stated that the advancement of OGM will enable comprehensive structural variant analysis to become routine, efficient, and accessible in laboratories, signaling a strategic shift for the company in the genomics field.
See More
Bionano Genomics Showcases OGM Technology for Enhanced Structural Variant Detection
- Technology Application Showcase: Bionano Genomics presented its optical genome mapping (OGM) technology at the 2025 AMP Annual Meeting, highlighting its superior clarity and sensitivity in detecting structural variants compared to traditional techniques, which is expected to drive broader applications in clinical and translational research.
- Research Findings Summary: A total of thirteen studies presented at the conference demonstrated OGM's potential in areas such as inherited diseases and tumors, indicating its capability as a high-resolution genomic technique that could transform the understanding of genetic mechanisms driving complex diseases.
- Laboratory Workflow Optimization: Researchers showcased how OGM can be successfully integrated into existing cytogenetics and next-generation sequencing workflows, streamlining laboratory processes and enhancing detection efficiency, which may improve operational effectiveness in labs.
- Future Development Commitment: Bionano CEO Erik Holmlin stated the company's commitment to innovating and expanding OGM technology, aiming to make comprehensive structural variant analysis routine, efficient, and accessible in laboratories, signaling a promising future market outlook.
See More
Bionano Laboratories Sees 47% Increase in 2026 CLFS for OGM Testing
- Fee Increase: Bionano Laboratories' CPT code 81195 sees a 47% increase in the 2026 Clinical Laboratory Fee Schedule, rising from $1,263.53 to $1,853.22, which will significantly enhance reimbursement for OGM testing related to blood cancers, thereby strengthening market competitiveness.
- Committee Support: The Clinical Diagnostic Laboratory Test Committee unanimously voted 10-0 in favor of reconsidering the payment standard for CPT code 81195, indicating strong industry recognition and confidence in OGM technology.
- Market Impact: The new pricing is expected to make Bionano's OGM-Dx™ product line more attractive, likely driving market share growth in hematologic malignancy testing and further solidifying its leadership position in genome analysis.
- Global Recognition: Bionano's Chief Medical Officer stated that the new payment level will not only facilitate the promotion of OGM testing in the U.S. market but also enhance global awareness of OGM applications in oncology and clinical genetic testing.
See More
Baidu Expected to Surge Over 69%: 10 Leading Analyst Predictions for Monday
Analyst Upgrades and Price Target Increases: JP Morgan upgraded Cipher Mining Inc and Baidu Inc, raising their price targets significantly, while B of A Securities upgraded Barrick Mining Corp's rating and price target as well.
Analyst Downgrades and Price Target Reductions: HC Wainwright & Co. downgraded BioNano Genomics Inc, and Jefferies downgraded Exact Sciences Corp despite increasing their price targets.
Mixed Analyst Ratings: Various analysts maintained or adjusted ratings for companies like Mp Materials Corp and Flutter Entertainment PLC, with some upgrades and downgrades occurring simultaneously.
Current Stock Prices: The article provides the latest closing prices for the mentioned stocks, indicating market performance and analyst sentiment.
See More
Bionano Genomics Initiates $10 Million Public Offering
Public Offering Announcement: Bionano Genomics, Inc. has launched a public offering of 5 million shares at $2.00 each, aiming to raise $10 million, with potential additional funds of $20 million if warrants are fully exercised.
Strategic Focus and Growth Plans: The company is enhancing utilization of its optical genome mapping and VIA software, aiming to expand into clinical and anatomic pathology while developing reimbursement support to increase profits and reduce costs.
See More
